Objectives: Drug resistance exists to all current and investigational antimalarial drug classes. Consequently, we have set out to develop chemically and mechanistically discrete antimalarials. Here we report on the development of thiosemicarbazone (TSC) antimalarials, with TSC3 as the most advanced lead.
Introduction
Malaria is the most important parasitic disease in the world. It is responsible for close to half a million deaths, with in excess of 200 million infections annually, and remains a target of critical interest in drug discovery. 1 There is now good clinical evidence of drug resistance to all current antimalarial agents, including the transmission of resistant parasite strains. [2] [3] [4] Consequently, the search for new antimalarials not subject to current resistance patterns with potentially new modes of action is of continued interest.
The current mainstays of antimalarial chemotherapy, the artemisinins (artesunate, artemether and dihydroartemisinin), are likely to exhibit their antimalarial activity through an interaction of the peroxidic function with ferrous iron and subsequent generation of reactive oxygen (as has been proposed for simple lipophilic peroxides), suggesting that the iron metabolism of the parasite can be targeted successfully. [5] [6] [7] The activity of the quinoline antimalarials such as chloroquine has been attributed to an interaction with ferriprotoporphyrin (or haem) resulting in a pH-dependent disruption in the parasitic haem detoxification mechanism. [8] [9] [10] Considerable uncertainty, however, remains as to the actual nature of this process. 11 The application of metal-chelating agents as antimalarials capitalizes on this concept.
Iron chelators figure predominantly as investigational antimalarials, with their probable mechanism of action being 2-fold: namely, depletion of labile iron required for metabolic processes and in situ formation of toxic iron species. 12 Iron chelators such as desferrioxamine (1, Figure 1 ) inhibit parasite growth both in vitro (although at relatively poor potency compared with other drugs, EC 50 of 20 lM averaged over 73 Plasmodium falciparum isolates) and in vivo with efficacy against human malaria in a clinical setting. [13] [14] [15] [16] The potency of other iron-chelating catechol-derived siderophores, such as FR160 and FBS0701 (2, Figure 1 ), is superior to desferrioxamine, but still relatively poor (EC 50 of 1.5 lM averaged over 137 P. falciparum isolates). 17, 18 Hydrazones and thiosemicarbazones derived from phenolic aldehydes, such as 2-hydroxy-1naphthaldehyde-4-phenyl-3-thiosemicarbazone (N4pT, 3, Figure 1 ), display similar anti-malarial potencies to FR160 and FBS0701 (2, Figure 1 ). For these latter agents, antiplasmodial activity is aided by lipophilic or bulky substituents, and potency is retained against chloroquine-resistant parasite strains. [17] [18] [19] [20] [21] We recently reported that metal-coordinating bis-thiosemicarbazones with a pyridyl core have promising antimalarial activity 22 (see Supplementary data available at JAC Online). A further 22 compound thiosemicarbazone test series was evaluated, from which 3 compounds exhibited potent in vitro antimalarial activities against the chloroquine-susceptible P. falciparum NF54 and the chloroquine-resistant P. falciparum Dd2 lines, with EC 50 s ,30 nM. We herein report ongoing studies in the evolution of this class of antimalarials, relating to thiosemicarbazones 8 (denoted BpNEt) and 16 (denoted TSC3; see Supplementary data).
Materials and methods

Synthesis of chelators and copper(II) complexes thereof
All thiosemicarbazones and their copper(II) complexes were synthesized according to standard procedures 23, 24 (see also Supplementary data).
Rodent parasites and mice for tolerability, efficacy and pharmacokinetic studies
The chloroquine-susceptible Plasmodium berghei ANKA was obtained from the Liverpool School of Tropical Medicine and Hygiene (Liverpool, UK). Swiss outbred ARC (Animal Resource Centre, Murdoch, Western Australia) female mice (5-7 weeks of age) were used in the present study. The mice received a standard mouse pellet diet (Rat and Mouse Food from Laucke Mills, Daveyston, South Australia) and tap water ad libitum. The animals were caged in groups of up to six per cage and held at a temperature of 24 C + 1 C at a relative humidity of 50% + 10%. For the tolerability, efficacy and pharmacokinetic studies of the thiosemicarbazones, the mean (+SD) body weight of the mice was 28.4+2.5 g (n"429).
Drugs
Artesunate and dihydroartemisinin were obtained from DK Pharma (Hanoi, Vietnam). Chloroquine diphosphate, mefloquine hydrochloride and tafenoquine succinate were obtained from Sigma-Aldrich Chemical Co. (St Louis, MO, USA). For tolerability, efficacy and pharmacokinetic studies in mice, BpNEt and TSC3 were prepared in 0.5% hydroxypropylmethylcellulose, 10% ethanol, 10% Tween 80 and 79.5% distilled water (dosage volume 0.2 mL).
Parasite cultures of P. falciparum
The chloroquine-and pyrimethamine-resistant line W2 (Indochina), the MDR (atovaquone, chloroquine and mefloquine) TM90-C2B (Thailand) and the artemisinin-susceptible (MRA1239) and artemisinin-resistant (MRA1240) P. falciparum laboratory-adapted isolates from Cambodia (BEI Resources Repository, USA) were cultured as described by Chavchich et al. 25 In vitro susceptibility of P. falciparum lines to thiosemicarbazone treatment
The activity of the drugs against the W2, TM90-C2B, MRA1239 and MRA1240 lines was assessed using the [ 3 H]hypoxanthine growth inhibition assay. 26 BpNEt and TSC3 were dissolved in DMSO at a concentration of 1 mM for the in vitro studies. Residual methanol and DMSO concentrations are too low to cause assay interference (data not shown). Briefly, the assays (in 96-well plates) were initiated when the majority of parasites (.95%) were at the ring stage. Parasite cultures (100 lL/well) at 1% initial parasitaemia and 2% haematocrit in complete, but hypoxanthine-free, medium were exposed to ten 2-fold serial dilutions of the compounds for 48 h/37 C, with [ 3 H]hypoxanthine (0.2 lCi/well) added 24 h after the beginning of the experiment. At least two independent experiments were carried out for each compound, with each assay performed in triplicate. The inhibitory concentrations (EC 50 and EC 90 ) were calculated by non-linear regression analysis using GraphPad Prism software V5.0 (GraphPad Software, Inc., CA, USA).
In vitro schizont maturation assay against P. berghei
The in vitro schizont maturation assay for testing BpNEt and TSC3 was based on the procedure of Chang et al. 27 BpNEt and TSC3 and the reference drugs, artesunate and chloroquine, were prepared as 30 mM stocks in DMSO (except chloroquine, which was dissolved in water) and diluted in complete medium prior to use (RPMI 1640 with 10% FCS). Blood (500 lL) was collected from a mouse infected with P. berghei at 3%-5% parasitaemia and enriched for early-stage parasites by passing it through a magnetic-activated cell sorting (MACS) column. Washed parasitized cells were made to 2% haematocrit in complete medium and added to triplicate wells of drug-containing microplates with final drug concentrations of 16 lM to 240 pM. Microplates were incubated at 37 C in 5% CO 2 for 22 to 24 h in a humidified environment.
Cells were subsequently gently resuspended to avoid rupture of schizonts, and 20 lL was transferred to a new microplate containing 180 lL of a 1/2000 dilution of Sybr Green (Invitrogen, Australia). 28 After incubating in the dark for 30 min, 100000 events/well were collected on a fluorescenceactivated cell sorting (FACS) Canto II flow cytometer (Becton Dickinson, Parkinson et al.
Australia). Giemsa-stained films of drug-free control wells were counted by microscopy to determine the percentage of schizonts, to allow for accurate setting of gates for statistical analysis of flow cytometry data. EC 50 values were calculated from non-linear regression analysis using GraphPad Prism software V5.0.
In vitro cytotoxicity in mammalian cell lines
The in vitro cytotoxicity of BpNEt and TSC3 against three mammalian cell lines (all sourced from the ATCC): HEK-293 (human embryonic kidney), HEP-G2 (human liver carcinoma) and BHK (baby hamster kidney) was determined using the alamarBlue (Invitrogen, Australia) fluorescence cell viability assay. 29 Cell cultures were maintained in complete RPMI 1640 medium (Sigma, USA) containing 10% FBS and 0.03% L-glutamine (complete medium) in 75 cm 2 flasks at 37 C with the medium changed twice weekly, as previously described. 30 BpNEt and TSC3 and the reference drugs, artesunate and chloroquine, were serially 2-fold diluted in triplicate using a master drug plate and tested at concentrations ranging from 120 lM to 60 nM.
In vivo tolerability assessment in mice
Tolerability assessment of BpNEt and TSC3 was performed in groups of three healthy mice to ensure that the compounds were tolerable. Four doses (oral gavage, volume 0.2 mL) administered at 24 h intervals were assessed: 8, 16 and 32 mg/kg/day for 4 days for both compounds and 64 mg/kg/day for 3 days for BpNEt. The animals were monitored for physical distress three times daily (typically between 7 am and 9 am, between 3 pm and 5 pm, and at 2 h after compound administration). Physical adverse events that were monitored included inability to move, reduced appetite, extreme pallor, ruffled hair and body weight loss (!16%). If any animal exhibited clinical adverse event signs that appeared highly stressful, they were euthanized.
In vivo efficacy in the Peters 4 day test
The Peters 4 day test measures the suppressive activity of blood schizonticides over 4 days at doses that do not cause physical stress in healthy mice. 31 BpNEt-and TSC3-treated and control female mice, in groups of six, were inoculated intraperitoneally with 20%10 6 P. berghei-infected RBCs (volume: 0.2 mL in physiological saline). Eight drug-treated groups with 2fold increases in dose (oral gavage, volume 0.2 mL) were assessed for both thiosemicarbazones and the reference drugs, artesunate and chloroquine. Untreated vehicle control (0.5% hydroxypropyl-methylcellulose, 10% ethanol, 10% Tween 80 and 79.5% distilled water, dosage volume 0.2 mL) mice typically die between days 6 and 7 post-infection. The drugs were administered $2 h after parasite inoculation (D0) and then daily at 24 h intervals for three consecutive days. Blood samples for blood thin films were collected on D ! 4 (with the number after the day, D, representing the total number of days since parasite inoculation).
In vivo efficacy in the modified Thompson test
The modified Thompson test determines the curative blood schizontocide dose given daily over 3 days with an established infection of $1%-3% parasitaemia. 32 
Parasitaemia monitoring in the mouse-P. berghei models
The degree of infection (i.e. parasitaemia) was determined from blood thin films that were collected by clipping the mouse's tail with a scalpel blade and 'milking' a drop of blood ($20 lL). The thin blood film slides were stained with 10% Giemsa for 15 min at room temperature and were read by a WHO-certified Level 1 malaria microscopist.
Analysis of parasitaemia suppression and radical cure in the mouse-P. berghei models
For the Peters 4 day test, inhibition of parasite growth in the BpNEt-, TSC3-, artesunate-and chloroquine-treated groups was calculated in relation to the non-treated control group. The suppressive difference between the mean parasitaemia value of the vehicle (control) group (taken as 100%) and those of the drug-treated groups was calculated and expressed as percentage reduction. Parasitaemia versus dose response and ED 50 (50% effective dose) and ED 90 (90% effective dose) values were calculated by non-linear regression analysis using GraphPad Prism V5.0. For the assessment of radical cure in the modified Thompson test, recurrence of P. berghei infection was tabulated for 31 days, at which time all mice surviving that were blood film negative were then deemed cured.
Pharmacokinetics in mice
The pharmacokinetics of the most potent thiosemicarbazone was determined in groups of five healthy female mice after a single oral dose of the compound. Blood samples (0.6 mL) were collected from each mouse by cardiac puncture at 0 (before dosing), 1, 3 and 6 h, and then at 1, 2, 3, 7, 10, 14, 21 and 28 days after dosing, and added to BD Microtainers containing EDTA as the anticoagulant (Becton Dickinson, Australia).
Blood samples (0.1-0.2 mL) were aliquotted into Eppendorf tubes and the remainder centrifuged at 14000 g for 5 min/4 C and plasma separated. Blood and plasma samples were stored at #80 C until LC-MS analysis for measurement of the thiosemicarbazone concentrations. The LC-MS method is described in the Supplementary data.
The pharmacokinetic parameters derived from the blood and plasma thiosemicarbazone concentration data were C max , T max , AUC and elimination t1 =2 , determined by non-compartment analysis (PK Solutions 2.0, Summit Research Services, OH, USA).
Ethical considerations
The animal studies covering mice infected with P. berghei for the in vitro schizont maturation assay, tolerability studies, in vivo efficacy studies in the mouse-P. berghei model and pharmacokinetic studies in mice were approved by the Defence Animal Ethics Committee (DAEC 04-15, 12-15, 06-16 and 02-17).
Results and discussion
Synthesis of the lead thiosemicarbazones
BpNEt and TSC3 (Figure 2) were synthesized as part of a structurally diverse ( Figure S1 ) thiosemicarbazone collection using a simple condensation protocol between a doubly aryl-substituted ketone and a thiosemicarbazide under acetic acid catalysis in refluxing ethanol according to literature protocols. 23, 24 The rationale behind the synthesis of the collection is described in the Supplementary data. Yields after crystallization for BpNEt and TSC3 were 47% and Development of antimalarial thiosemicarbazones JAC 61%, respectively. These two candidates were selected for further study on the basis of our antimalarial drug prioritization flowsheet (Figure 3 ).
In vitro antimalarial activities of the lead thiosemicarbazones against P. falciparum lines
As a follow-up to our earlier study, 22 we set out to develop the thiosemicarbazone class as new antimalarials. The two lead TSCs (BpNEt and TSC3) were initially selected based on their in vitro potency against the two P. falciparum lines (NF54 and Dd2, Table S1 ). These studies revealed that the presence of two aryl residues appeared necessary for activity against the chloroquine-resistant P. falciparum Dd2 parasites. Of note, this structural feature was not included in an earlier series identified by Klayman et al. 33, 34 Further appraisal against MDR P. falciparum lines showed TSC3 to be markedly more potent in vitro than BpNEt by 3-to 4-fold based on EC 50 values (Table 1 ). Furthermore, TSC3 was $10-fold more potent than chloroquine and mefloquine against the highly resistant TM90-C2B and MRA1240 lines, but less potent than dihydroartemisinin.
In vitro antimalarial activities of the lead thiosemicarbazones against P. berghei
In addition to assessing the in vitro activities of the two thiosemicarbazones against P. falciparum lines, the compounds were assessed in the in vitro P. berghei schizont maturation assay for future planning for in vivo efficacy studies in the mouse-P. berghei model.
Unlike the results in the in vitro studies against the MDR P. falciparum lines, TSC3 (50 nM) exhibited EC 50 values $2-fold higher than that of chloroquine (32 nM) and artesunate (20 nM; Table 2 ). However, we concluded that the activity against P. berghei in vitro should be a good predictor of potency in the mouse-P. berghei model and potential efficacy against P. falciparum in an in vivo model. Furthermore, the activity against P. falciparum may, in fact, be superior to activity against P. berghei for this hit series.
Detailed evaluation of mammalian cell-based toxicity in vitro
Early single concentration mammalian toxicity studies of the thiosemicarbazone test series listed in the Supplementary data against MRC-5 human lung fibroblasts at 20 lM failed to indicate toxic effects. However, we chose to initiate an additional study of cytotoxic potential against three further mammalian cell lines to verify the early toxicity data using a multi-concentration (dose-response) approach described in this study. A neoplastic cell line was included in this assessment, the basis for this being that related drugs were developed to display selective cytotoxicity towards cancerous cells. 35, 36 While not strictly transferable to human toxicity, we also chose to use a non-transformed rodent cell line (BHK) prior to assessing tolerability in mice.
After calculating a selectivity index (SI; Table 3 ), we concluded that there would be a sufficient therapeutic window for evaluation of TSC3 as an antimalarial therapy. 37 The in vitro data for TSC3 suggest that potency against the W2 line would be obtained at a concentration some 39 times lower than the onset of toxicity for the HEK-293 cells. This threshold is considerably wider for the BHK cells and the HEP-G2 cells, with SI values of 510 and 602, respectively. The average SI was $1500 for the chloroquine-susceptible NF54 parasite and almost 400 for the chloroquine-resistant W2 parasite (see definition in the footnotes of Table 3 ). Accordingly, we decided that an in vivo study was warranted to assess the tolerability of the thiosemicarbazones.
Tolerability studies in mice
The tolerability of BpNEt and TSC3 was assessed in mice administered by oral gavage in four ascending daily doses of 8, 16, 32 and 64 mg/kg/day for BpNEt and 8, 16 and 32 mg/kg/day for TSC3. BpNEt was well tolerated in groups of three mice at all concentrations up to and including 64 mg/kg/day. Some mice exposed to TSC3 at 32 mg/kg/day experienced adverse reactions after 3 days of dosing, showing symptoms of severe hunching, markedly decreased activity and excessive coat ruffling (these mice were euthanized). Nonetheless, TSC3 was well tolerated over the four dose regimen at 16 mg/kg/day. Consequently, all subsequent studies with TSC3 were carried out with a dosage ceiling of 16 mg/kg/day.
Efficacy in the mouse-P. berghei model
In the Peters 4 day test using a dose range of 0.125-16 mg/kg/day, TSC3 was 5.6-fold more effective in suppressing the lethal P. berghei ANKA strain than BpNEt (ED 50 values: 1.2 mg/kg/day versus 7.8 mg/kg/day) (Table 4, Figure 4 ).
When compared with the two reference drugs, TSC3 had potency comparable to artesunate (ED 50 1.2 mg/kg/day) and was $2.4-fold more potent than chloroquine (ED 50 3.3 mg/kg/day). However, the Peters 4 day test (carried out 24 h after the final dose of drug) does not cater to determining the suppression activity beyond the completion timepoint.
On the basis of these suppression data, we concluded that BpNEt was insufficiently potent after oral administration and, consequently, all further studies were conducted on the more potent agent, TSC3.
To further evaluate the therapeutic potential of TSC3, we assessed the ability of the thiosemicarbazone to effect radical cure in the modified Thompson test, which requires extended follow-up for 4 weeks post-treatment. Evaluation of a dose range of 1-16 mg/kg/day of TSC3 given daily for 3 days with continued parasitaemia monitoring after dosage provided the opportunity to assess the thiosemicarbazone's capability to clear an established Table S1 ).
Parkinson et al. Development of antimalarial thiosemicarbazones JAC P. berghei infection and to prevent recrudescence. These data were compared with a parallel assessment of the reference drugs artesunate and chloroquine. At doses of 4 mg/kg/day, TSC3 failed to elicit complete parasite clearance (data not shown). Clearance was observed on day 5 post-treatment in 50% of six mice at doses of 8 mg/kg/day, with reappearance of parasites on day 8 post-treatment (Table 5) . At the highest dose tested, all six mice cleared the P. berghei infection at 16 mg/kg/day by day 4 post-treatment. However, one mouse had to be euthanized because of significant body weight loss (.16%), with recrudescence of a second mouse 10 days after commencing treatment. Four mice in this treatment cohort showed no recurrence of infection by day 31 and were deemed cured.
This study was repeated with similar results, with an overall cure rate of 58% (7/12 mice). In contrast, artesunate and chloroquine at a dose of 64 mg/kg/day cleared infection at days 1 and 3, with recrudescence occurring at days 3 and 8, respectively, with no mice surviving to day 31 (0% cure).
Pharmacokinetic evaluation
The assessment of in vivo potency for TSC3 suggested that the thiosemicarbazone was highly persistent in the mouse model. This pharmacodynamic finding suggests that TSC3 could have a relatively lengthy blood elimination half-life. The pharmacokinetic properties of TSC3 were evaluated in healthy mice administered a single oral dose of 16 mg/kg of TSC3. Calibration and quality control data for blood and plasma analyses can be viewed in the Supplementary data (Tables S2-S10). The mean (SD) blood and plasma concentration versus time profiles of TSC3 are shown in Figure 5 (the full data set is available in the Supplementary data, Tables S11 and S12).
The thiosemicarbazone was absorbed rapidly, followed by concentration-dependent clearance approximating behaviour characteristic of a single compartment model in both blood and plasma samples. The mean blood concentration data of TSC3 revealed a C max of 1883 ng/mL with a T max of 1 h and an elimination t1 =2 of 48.7 h (Table 6) . Published values for the elimination t1 =2 of related thiosemicarbazones Triapine and Dp44mT are 1 h (human data) and 2.2 h (rat), respectively, illustrating that TSC3 is far more persistent in vivo than related drugs. 38, 39 This level of persistence for TSC3 suggests that a refined dosage regimen Parkinson et al.
for the in vivo studies may be desirable (the current dosage interval is $50% of half-life) to avoid accumulation of the drug (a loading dose and smaller follow-up doses may be warranted). Toxicity of earlier thiosemicarbazones is highly dose dependent and varies substantially with drug structure, ranging from resolvable leucopenia to cardiotoxicity (reported only for Dp44mT after 2 weeks of intense, non-optimal dose administration). 36, [38] [39] [40] No evidence of cardiotoxicity was detected in the current study. Development of antimalarial thiosemicarbazones JAC Plasma TSC3 concentrations paralleled blood concentrations, with a blood to plasma concentration ratio based on AUC values of 2, suggesting an association of the thiosemicarbazone with blood cells.
Ongoing research
As the lead thiosemicarbazone, TSC3 has excellent potency and oral efficacy; current studies have been initiated to refine both pharmacodynamic and pharmacokinetic properties and to elucidate the mechanism of action of this antimalarial class.
Conclusions
Pyridyl thiosemicarbazones offer a promising alternative to current chemotherapeutic options for the treatment of malaria. Notably, thiosemicarbazones are simple to synthesize (resulting in an extremely low cost of goods) and chemically robust. Both these properties are desirable characteristics for development of antimalarial drugs. The lead thiosemicarbazone, TSC3, was highly potent against MDR P. falciparum lines and also demonstrated high in vivo potency in the mouse-P. berghei model. In fact, TSC3 was at least as potent as artesunate and chloroquine. This efficacy of TSC3 is reflected in the compound's suitable oral exposure and potential duration of action with a blood elimination t1 =2 of 48 h in mice.
